Protocol Update and Issues in EASTYLE Trial

초록

The EASTYLE study is currently ongoing, based on the hypothesis that ticagrelor reduction and a 3-month aspirin removal strategy (Hybrid De-escalation) as part of the de-escalation strategy can reduce cardiovascular complications (net clinical outcome). There have been no previous studies on the reduction effect of ticagrelor, and this study involves 35 sites in Korea, showing a registration rate of around 20% currently. Registration is expected to close in early or mid 2025, and results are anticipated to be announced around the same time as the ELECTRA-SIRIO 2 study.

키워드